Covidien Introduces Permacol TM Biologic Implant

Covidien (NYSE: COV, BSX: COV), a leading global provider of healthcare products, today announced the launch of Permacol TM Biologic Implant, a biologic mesh for hernia repair. Permacol TM, which joins the Company´s line of products following the acquisition of Tissue Science Laboratories, is available in the United States, Europe, Canada and Korea and will be registered in other markets starting in 2009.

"As a leader in soft tissue repair, Covidien now offers the optimal hernia repair product for individual patient needs, including biologic implants, synthetic mesh, fixation and dissection devices," said Scott Flora, President, Surgical Devices, Covidien.

Permacol TM Biologic Implant contains enhanced porcine collagen for complex hernias and abdominal wall repairs. The product combines the clinical advantages of a biologic with the strength, size, and intraoperative efficiency of a synthetic in an accellular porcine dermal implant. Permacol TM Biologic Implant, which is hydrated and ready–to–use, can be cut or shaped to size as needed and provides a stable, durable soft tissue repair.

For more information on Permacol TM Biologic Implant, please visit www.covidien.com/hernia. This new website includes information on the complete line of hernia solutions provided by Covidien Surgical Devices.

ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry–leading product lines in four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2007 revenue of nearly $9 billion, Covidien has more than 42,000 employees worldwide in 57 countries, and its products are sold in over 130 countries. Please visit www.covidien.com to learn more about our business.